Readline Biotech

Readline is committed to becoming a global leader in next-generation green active ingredients, adopting next-generation synthetic biology technologies and focusing on achieving green production of active ingredients such as peptides, proteins, sugars, and nucleic acids. Relying on more than 20 years of scientific research accumulation and industrial experience of its founding team, the company has successfully built a multidisciplinary integrated technology platform and has now achieved mass production of dozens of green active ingredients, including semaglutide, tirzepatide, S-boswellia, collagen peptides, ergothioneine, NMN, blue copper peptides, NAD+, ectoine, carnosine series, glutathione series, and various peptides, cumulatively providing high-quality green active ingredients to nearly a thousand well-known enterprises in fields such as biopharmaceuticals, functional skincare, and nutrition & health.
After seven years of rapid development, Readline has ranked among the top domestic peers in terms of R&D investment, enterprise scale, and output of results. It has applied for more than a hundred invention patents and has won multiple national and local honorary titles, including National Specialized, Refined, Distinctive and Innovative Little Giant, National High-tech Enterprise, Shenzhen Specialized, Refined, Distinctive and Innovative SME, Shenzhen Potential Unicorn Enterprise, Shenzhen Postdoctoral Innovation Practice Base, Shenzhen Top 30 Medical Health Innovation, Zhuhai Innovation and Entrepreneurship Team, and Gansu Province Specialized, Refined, Distinctive and Innovative SME. In addition, in 2022, the company was listed in the Shenzhen Top 100 High-growth Enterprises list (ranking first among unlisted biotech enterprises), and in 2023 it was selected by Harvard Business Review as a High-energy Innovation Team, demonstrating the company's outstanding strength and innovation potential in the industry.